MedTrace Logo

Study of 18F-Thretide PET/CT in Patients With Prostate Cancer

NCT05516329 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2023-09-21

No results posted yet for this study

Summary

This study evaluates the diagnostic performance and safety of 18F-Thretide PET/CT in patients with biopsy proven prostate cancer who has no any form of therapy against prostate caner or suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.

Conditions

Interventions

DRUG

A single dose of 7±1 mCi (259±37 MBq) IV injection of 18F-Thretide

The patients will be intravenously injected with 18F-Thretide and undergo PET/CT scan at 60\~120 min after the injection.

Sponsors & Collaborators

  • First Affiliated Hospital of Fujian Medical University

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-20
Primary Completion
2023-03-31
Completion
2023-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05516329 on ClinicalTrials.gov